Phage Therapy Investigated for Cystic Fibrosis
Enrollment has begun in an early-stage clinical trial evaluating phage therapy (bacteriophage) in adults with cystic fibrosis who carry Pseudomonas aeruginosa in their lungs.
Enrollment has begun in an early-stage clinical trial evaluating phage therapy (bacteriophage) in adults with cystic fibrosis who carry Pseudomonas aeruginosa in their lungs.
Mucus uses glycans in concert with mucins to "regulate" the behavior of bacteria like Pseudomonas aeruginosa, preventing bacterial communication and biofilm formation, according to MIT research.